	US 11,918,562 B2
	Combination therapy using azabicyclo compound for cancer
Hiromi Muraoka, Tsukuba (JP); and Akira Kanoh, Tsukuba (JP)
Assigned to TAIHO PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed by TAIHO PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed on Sep. 30, 2021, as Appl. No. 17/490,256.
Application 17/490,256 is a division of application No. 16/877,959, filed on May 19, 2020, granted, now 11,166,943.
Application 16/877,959 is a division of application No. 15/493,479, filed on Apr. 21, 2017, granted, now 10,849,886, issued on Dec. 1, 2020.
Application 15/493,479 is a continuation of application No. 15/025,797, granted, now 9,694,001, issued on Jul. 4, 2017, previously published as PCT/JP2014/075846, filed on Sep. 29, 2014.
Claims priority of application No. 2013-205500 (JP), filed on Sep. 30, 2013.
Prior Publication US 2022/0016090 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61K 31/337 (2006.01); A61K 31/454 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/555 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01)

CPC A61K 31/437 (2013.01) [A61K 31/337 (2013.01); A61K 31/454 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/555 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01)]

8 Claims

1. A method for treating a at least one tumor selected from the group consisting of epidermal cancer, malignant melanoma, multiple myeloma, acute myelocytic leukemia, large intestine cancer, lung cancer, gallbladder cancer, stomach cancer, and breast cancer, comprising:

administering to a patient 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a salt thereof and at least one other antitumor agent selected from the group consisting of docetaxel, paclitaxel, cisplatin, amrubicin, crizotinib, 5-fluorouracil (5-FU), 5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzimidazole-6-carbohydroxamic acid 2-hydroxyethyl ester (ZD6244), SN-38, imatinib, etoposide, erlotinib, oxaliplatin, gefitinib, gemcitabine, cytarabine, dasatinib, doxorubicin, vemurafenib, pemetrexed, bortezomib, mytomycin C, lapatinib, and lenalidomide,

wherein,

a molar ratio of the 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a salt thereof to the other antitumor agent is from 1: 0.00014 to 3645.